Skip to main content
SpringerLink
Log in

Interstitielle Lungenerkrankung

Taugt bei akut exazerbierter idiopathischer Lungenfibrose der Kortisonstoß noch?

  • cme fortbildung
  • Published:
Pneumo News Aims and scope

Zusammenfassung

Die akute Exazerbation einer idiopathischen Lungenfibrose (AE-IPF) ist definiert als akute respiratorische Verschlechterung bei IPF-Patienten. Für die Diagnosestellung müssen bestimmte Kriterien erfüllt sein. Ursache und Pathophysiologie des Krankheitsbildes sind noch nicht genau verstanden. Die Prognose einer AE-IPF ist sehr schlecht und konsertierte Therapiemaßnahmen sind noch nicht etabliert, wenn auch eine hochdosierte Steroidtherapie in der Klinik regelhaft angewandt wird.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Raghu G, Collard HR, Egan JJ et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824

    Article  Google Scholar 

  2. Ley B, Collard HR, King TE, Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–40

    Article  Google Scholar 

  3. Kreuter M, Ehlers-Tenenbaum S, Palmowski K et al. Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PloS one. 2016;11(3):e0151425

    Article  Google Scholar 

  4. Kreuter M, Swigris J, Pittrow D et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practicinsights-IPF registry. Respir Res. 2017;18(1):139

    Article  Google Scholar 

  5. Behr J, Gunther A, Bonella F et al. [German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017]. Pneumologie. 2017;71(7):474

    Article  Google Scholar 

  6. Kim DS, Park JH, Park BK et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27(1):143–50

    Article  CAS  Google Scholar 

  7. Simon-Blancal V, Freynet O, Nunes H et al. Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration. 2012;83(1):28–35

    Article  CAS  Google Scholar 

  8. Collard HR, Ryerson CJ, Corte TJ et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265–75

    Article  CAS  Google Scholar 

  9. Molyneaux PL, Cox MJ, Wells AU et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res. 2017;18(1):29

    Article  Google Scholar 

  10. Petrosyan F, Culver DA, Reddy AJ. Role of bronchoalveolar lavage in the diagnosis of acute exacerbations of idiopathic pulmonary fibrosis: a retrospective study. BMC Pulm Med. 2015;15:70

    Article  Google Scholar 

  11. Collard HR, Yow E, Richeldi L et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73

    Article  Google Scholar 

  12. Lee JS, Song JW, Wolters PJ et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012;39(2):352–8

    Article  CAS  Google Scholar 

  13. Lee JS, Collard HR, Anstrom KJ et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369–76

    Article  Google Scholar 

  14. Johannson KA, Vittinghoff E, Lee K et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J. 2014;43(4):1124–31

    Article  Google Scholar 

  15. Kuhn C, 3rd, Boldt J, King TE, Jr. et al. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis. 1989;140(6):1693–703

    Article  Google Scholar 

  16. Konishi K, Gibson KF, Lindell KO et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;180(2):167–75

    Article  CAS  Google Scholar 

  17. Collard HR, Calfee CS, Wolters PJ et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(1):L3–7

    Article  CAS  Google Scholar 

  18. Moeller A, Gilpin SE, Ask K et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. 2009;179(7):588–94

    Google Scholar 

  19. Maharaj S, Shimbori C, Kolb M. Fibrocytes in pulmonary fibrosis: a brief synopsis. Eur Respir Rev. 2013;22(130):552–7

    Article  Google Scholar 

  20. Gunther A, Korfei M, Mahavadi P, von der Beck D, Ruppert C, Markart P. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev. 2012;21(124):152–60

    Article  Google Scholar 

  21. Qiu M, Chen Y, Ye Q. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Clin Respir J. 2018;12(3):1084–92

    Article  CAS  Google Scholar 

  22. Kondoh Y, Taniguchi H, Katsuta T et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):103–10

    CAS  PubMed  Google Scholar 

  23. Kolek V, Vasakova M, Sterclova M et al. [Radiotherapy of Lung Tumours in Idiopathic Pulmonary Fibrosis]. Klin Onkol. 2017;30(4):303–6

    Article  CAS  Google Scholar 

  24. Sakamoto K, Taniguchi H, Kondoh Y et al. Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir Med. 2012;106(3):436–42

    Article  Google Scholar 

  25. Suzuki H, Sekine Y, Yoshida S et al. Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today. 2011;41(7):914–21

    Article  Google Scholar 

  26. Ghatol A, Ruhl AP, Danoff SK. Exacerbations in idiopathic pulmonary fibrosis triggered by pulmonary and nonpulmonary surgery: a case series and comprehensive review of the literature. Lung. 2012;190(4):373–80

    Article  Google Scholar 

  27. Papiris SA, Kagouridis K, Kolilekas L et al. Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach. BMC Pulm Med. 2015;15:162

    Article  Google Scholar 

  28. Kreuter et al. A global perspective on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): results from an international survey. ERS 2018 International Congress, Vortrag OA542, 16.9.2018

  29. Donahoe M, Valentine VG, Chien N et al. Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis. PloS one. 2015;10(6):e0127771

    Article  Google Scholar 

  30. Sakamoto S, Homma S, Miyamoto A et al. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010;49(2):109–15

    Article  CAS  Google Scholar 

  31. Horita N, Akahane M, Okada Y et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2011;50(3):189–95

    Article  CAS  Google Scholar 

  32. Abe S, Hayashi H, Seo Y et al. Reduction in serum high mobility group box-1 level by polymyxin B-immobilized fiber column in patients with idiopathic pulmonary fibrosis with acute exacerbation. Blood Purif. 2011;32(4):310–6

    Article  CAS  Google Scholar 

  33. Isshiki T, Sakamoto S, Kinoshita A et al. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respiration. 2015;89(3):201–7

    Article  CAS  Google Scholar 

  34. Kawamura K, Ichikado K, Yasuda Y et al. Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study. BMC Pulm Med. 2017;17(1):94

    Article  Google Scholar 

  35. Kistler KD, Nalysnyk L, Rotella P, Esser D. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med. 2014;14:139

    Article  Google Scholar 

  36. Dotan Y, Vaidy A, Shapiro W et al. Effect of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplantation Outcome. Chest. 2018. https://doi.org/10.1016/j.chest.2018.06.027

    Article  Google Scholar 

  37. Rush B, Wiskar K, Berger L, Griesdale D. The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: A nationwide retrospective cohort analysis. Respir Med. 2016;111:72–6

    Article  Google Scholar 

  38. Johannson K, Collard HR. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal. Curr Respir Care Rep. 2013;2(4). https://doi.org/10.1007/s13665-013-0065-x

    Article  CAS  Google Scholar 

  39. Lee JS, Ryu JH, Elicker BM et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1390–4

    Article  Google Scholar 

  40. Kreuter M, Wuyts W, Renzoni E et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. 2016;4(5):381–9

    Article  CAS  Google Scholar 

  41. Meyer KC, Raghu G, Baughman RP et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004–14

    Article  Google Scholar 

  42. Behr J, Gunther A, Bonella F, et al. [German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017]. Pneumologie. 2017;71(7):460–74

    Article  Google Scholar 

  43. Richeldi L, Costabel U, Selman M et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–87

    Article  CAS  Google Scholar 

  44. Richeldi L, du Bois RM, Raghu G et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82

    Article  Google Scholar 

  45. Richeldi L, Cottin V, du Bois RM et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS((R)) trials. Respir Med. 2016;113:74–9

    Article  Google Scholar 

  46. Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040–7

    Article  Google Scholar 

  47. Ley B, Swigris J, Day BM et al. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017;196(6):756–61

    Article  Google Scholar 

  48. Iwata T, Yoshida S, Nagato K et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today. 2015;45(10):1263–70

    Article  Google Scholar 

  49. Taniguchi H, Ebina M, Kondoh Y et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–9

    Article  CAS  Google Scholar 

  50. Sekine Y, Ko E. [The influence of intraoperative oxygen inhalation on patients with idiopathic pulmonary fibrosis]. Masui. 2011;60(3):307–13

    PubMed  Google Scholar 

  51. Mizuno Y, Iwata H, Shirahashi K et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg. 2012;41(6):e161–5

    Article  Google Scholar 

  52. Polke et al. Diagnosis and therapy of acute exacerbations of acute pulmonary fibrosis (AE-IPF) in Germany. ERS 2018 International Congress, Vortrag PA2903, 17.9.2018

Download references

Author information

Authors and Affiliations

  1. Zentrum für interstitielle und seltene Lungenerkrankungen, Pneumologie, Thoraxklinik, Universitätsklinkum Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Deutschland

    Markus Polke &  Michael Kreuter

Authors
  1. Markus Polke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Kreuter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Polke.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen und dass keine potenziellen Interessenkonflikte vorliegen.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CMEFragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Polke, M., Kreuter, M. Taugt bei akut exazerbierter idiopathischer Lungenfibrose der Kortisonstoß noch?. Pneumo News 10, 31–38 (2018). https://doi.org/10.1007/s15033-018-0817-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-018-0817-y

Search

Navigation